12-Dec-2025
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts
TipRanks (Sat, 13-Dec 4:02 AM ET)
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
Benzinga (Fri, 12-Dec 1:51 PM ET)
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
PRNewswire (Fri, 12-Dec 10:48 AM ET)
ImmunityBio, Moderna among winners of EU drug recommendations this week
Seeking Alpha News (Fri, 12-Dec 10:45 AM ET)
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week
Seeking Alpha News (Fri, 12-Dec 10:45 AM ET)
Short bets on S&P 500 Healthcare sector rises to 2.12% in November; MRNA stays most shorted stock
Seeking Alpha News (Fri, 12-Dec 9:35 AM ET)
This QXO Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga (Fri, 12-Dec 8:51 AM ET)
Morgan Stanley Keeps Their Hold Rating on Moderna (MRNA)
TipRanks (Fri, 12-Dec 8:25 AM ET)
FDA plans to put “black box” warning on Covid vaccines: report
Seeking Alpha News (Fri, 12-Dec 6:45 AM ET)
Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating
TipRanks (Thu, 11-Dec 8:05 PM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of December 12, 2025, MRNA stock price declined to $29.46 with 11,620,934 million shares trading.
MRNA has a beta of 1.47, meaning it tends to be more sensitive to market movements. MRNA has a correlation of 0.15 to the broad based SPY ETF.
MRNA has a market cap of $11.51 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $1 billion in Revenue and -$.51 earnings per share. This beat revenue expectation by $150 million and exceeded earnings estimates by $1.66.
In the last 3 years, MRNA traded as high as $217.25 and as low as $22.28.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, VB, RSP, XBI.
MRNA has underperformed the market in the last year with a return of -31.2%, while SPY returned +14.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRNA shares. However, MRNA has outperformed the market in the last 3 month and 2 week periods, returning +25.3% and +13.4%, while SPY returned +4.0% and -0.2%, respectively. This indicates MRNA has been having a stronger performance recently.
MRNA support price is $28.40 and resistance is $30.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA shares will trade within this expected range on the day.